NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.63 against a street estimate of 1.00 — a miss of 163.0%.
with an average price target of ₹508.33.
MIXED Q1 FY'27 was intentionally weak; recovery underway with restocking orders and new commercial programs. Oligonucleotides doubled. ADC and small molecule CDMO show pipeline strength but profitability challenged. Q1 FY'27 No geographic breakdown provided in call. Analysts pressed for small molecule competitive differentiation, Phase III commercial upside, and destocking recovery timing. Management stressed relationship depth, science capabilities, and pipeline confidence rather than market share tactics, and deferred destocking quantification pending second molecule clarity. 2026-08-05…
Full summary in the app.
| Document | Date |
|---|---|
| Annual report FY2026 COHANCE LIFESCIENCES LIMITED - FY26 SUMMARY HEADLINE NUMBERS • Consolidated revenue: ₹22.68 billion (FY26) • Adjusted EBITDA: ₹4.8 billion with cons | 2026-08-26 |
| Q1 FY27 earnings call COHANCE LIFESCIENCES LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenue from operations: INR 4,223 million, down 23% year-on | 2026-08-11 |
| Investor presentation · Q1 FY27 COHANCE LIFESCIENCES LIMITED – Q1 FY2027 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue: INR 4,223 Mn (Q1 FY27), down 23.1% year-on-year • Adjust | 2026-08-05 |
| Quarterly results · Q1 FY27 COHANCE LIFESCIENCES LIMITED – Q1 FY2027 (Quarter ended 30 June 2026) HEADLINE NUMBERS • Standalone Revenue from Operations: ₹359.89 crores (Q1 FY27 | 2026-08-05 |
| Quarterly results | 2026-07-20 |
| Q4 FY26 earnings call COHANCE LIFESCIENCES LIMITED – FY26 EARNINGS SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 22.68 billion (down 13% year-on-year from INR 26.09 billio | 2026-05-15 |
| Investor presentation · Q4 FY26 COHANCE LIFESCIENCES LIMITED - INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: INR 22.68 Bn (down 13.0% YoY from INR 26.09 Bn in FY25) • Adj | 2026-05-12 |
| Quarterly results · Q4 FY26 COHANCE LIFESCIENCES LIMITED - FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • FY 2026 Standalone Revenue: ₹2,030.50 crores (down 18.9% fr | 2026-05-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cohance Lifesciences Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.